We previously showed that Na ؉ /H ؉ -exchanger regulatory factor-1/Ezrin-radixin-moesin-binding phosphoprotein-50 (NHERF-1/EBP50) co-immunoprecipitated with the human opioid receptor (hKOR) and that its overexpression blocked the agonist U50,488H-induced hKOR down-regulation by enhancing recycling. Here, we show that glutathione S-transferase (GST)-hKOR Ctail interacted with purified NHERF-1/EBP50, whereas GST or GST-C-tails of or ␦ opioid receptors did not. 
The opioid receptor (KOR) 1 is one of the multiple types (at least , ␦, and ) of opioid receptors that mediate pharmacological effects of opioid drugs and physiological actions of endogenous peptides. Activation of opioid receptors in vivo results in many effects, including analgesia (1-3), dysphoria (2) (3) (4) , and water diuresis (1, 2) . At cellular levels, stimulation of opioid receptors activates G i /G o proteins resulting in downstream changes, such as inhibition of adenylyl cyclase, activation of p42/p44 mitogen-activated protein (MAP) kinase, increase in K ϩ conductance, and decrease in Ca 2ϩ conductance (for a review, see Ref. 5) . opioid receptors of the human, rat, mouse, and guinea pig have been cloned (for reviews, see Refs. 6 and 7), and the receptors belong to the rhodopsin subfamily of G protein-coupled receptors (GPCRs) (8) .
PDZ domains were originally identified in the proteins postsynaptic density-95 (PSD-95), discs-large, and zona occludens-1 (ZO-1) as repeats of about 90 amino acids containing the conserved motif Gly-Leu-Gly-Phe. These domains mediate protein-protein interactions by interacting with the last few Cterminal residues of their target proteins (9, 10) . Many GPCRs have been shown to interact with PDZ domain-containing proteins, and such interactions play important roles in signal transduction and receptor regulation (for a review, see Ref. 11) . Na ϩ /H ϩ exchanger regulatory factor-1 (NHERF-1)/ezrin-radixin-moesin (ERM)-binding phosphoprotein-50 (EBP50) is a PDZ domain-containing protein. Rabbit NHERF-1 was first purified and cloned (12) , and the human homolog was subsequently cloned, termed EBP50 (13) or hNHERF (14) . The term 1 The abbreviations used are: KOR, opioid receptor; hKOR, human opioid receptor; ␤ 2 -AR, ␤ 2 -adrenergic receptor; BCECF-AM, acetoxymethyl ester of 2Ј,7Јbis-(2-carboxyethyl)-5(6)-carboxyfluorescein; CHO cells, Chinese hamster ovary cells; DI and DII, NHERF-1/EBP50 PDZ domains I and II; FL, full-length NHERF-1/EBP50; GPCR, G protein-coupled receptor; GST, glutathione S-transferase; HA, hemagglutinin epitope (YPYDVPDYA); hdor, human ␦ opioid receptor; hmor, human opioid receptor; HRP, horseradish peroxidase; MAP, mitogenactivated protein; NHE3, Na ϩ /H ϩ exchanger 3; NHERF-1/EBP50, Na ϩ /H ϩ exchanger regulatory factor-1/ezrin-radixin-moesin (ERM)-binding phosphoprotein-50; nor-BNI, norbionaltorphimine; OK cells, opossum kidney proximal tubule epithelial cells; PDZ, PSD-95/Discslarge/ZO-1 homology; PTX, pertussis toxin; PSD-95, post-synaptic density protein of 95 kDa; TMA, tetramethylammonium; U50,488H, (Ϫ)(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)cyclohexyl]benzeneacetamide; OKH, the clonal subline "H" of OK cells; PVDF, polyvinylidene difluoride; MOPS, 4-morpholinepropanesulfonic acid; GTP␥S, guanosine-5Ј-O-(3-thiotriphosphate); PKA, protein kinase A; PKC, protein kinase C.
NHERF-1/EBP50 is used throughout this report. NHERF-1/ EBP50 is widely distributed in tissues and is particularly enriched in those containing polarized epithelia. NHERF-1/ EBP50 is a cofactor essential for cAMP-mediated inhibition of the activity of Na ϩ /H ϩ exchanger 3 (NHE3), a subtype of the Na ϩ /H ϩ exchangers found in renal apical membranes. Through the ERM-binding domain, NHERF-1/EBP50 binds to the ezrinradixin-moesin family of actin-binding proteins and thus joins NHE3 with the actin cytoskeleton. This complex facilitates NHE3 phosphorylation and hormonal regulation of Na ϩ /H ϩ exchange (for reviews, see Refs. 15 and 16) . In renal proximal tubules, NHE3 secrets H ϩ into the lumen that, in turn, leads to the production of HCO 3 Ϫ , which re-enters the blood. Such NHE3-initiated ion transport mediates the re-absorption of NaCl and NaHCO 3 .
Hall et al. (17) have shown that NHERF-1/EBP50 is associated with the ␤ 2 -AR, and this interaction plays an important role in ␤ 2 -AR-mediated regulation of the NHE3 activity independent of G proteins. This finding resolves the paradox, that activation of ␤ 2 -AR enhances intracellular cAMP but does not inhibit NHE3 activity. The observation revealed a mechanism by which GPCRs, such as ␤ 2 -AR, through their associated protein(s), influence cellular signaling events independent of G proteins.
We have recently demonstrated that NHERF-1/EBP50 coimmunoprecipitates with the human opioid receptor (hKOR) via its first PDZ domain (18) . This association appears to serve as a signal for internalized hKOR to be sorted to the recycling pathway and thus blocks U50,488H-induced down-regulation of the hKOR, without affecting its internalization (18) . The C-terminal sequence of the hKOR, NKPV, is distinctly different from the sequence, D(S/T)XL, the optimal C-terminal motif in the ␤ 2 -AR for NHERF-1/EBP50 binding (19) .
Although NHERF-1/EBP50 co-immunoprecipitates with the hKOR and it appears to be a PDZ domain-mediated interaction (18), it is not clear whether NHERF-1/EBP50 binds directly to the C-terminal domain of the hKOR. In this study, we employed the pull-down techniques using the fusion protein of glutathione S-transferase (GST) and the C-terminal domain of the hKOR (GST-hKOR C-tail) to examine its interaction with NHERF-1/EBP50, purified from a bacterial expression system, expressed in CHO cells and endogenously expressed in OK cells, a cell line derived from opossum kidney proximal tubules. As in OK cells, NHERF-1/EBP50 is known to be a regulator of NHE3 (16, 28) , and opioid binding sites have been shown to be present (20) ; thus, we examined in these cells whether activation of the opioid receptor regulates Na ϩ/ H ϩ exchange, and, if so, whether NHERF-1/EBP50 plays a role. cDNA Construction and Purification of GST Fusion Proteins-Six GST fusion proteins were used in the studies: GST-hKOR C-tail, GSThmor C-tail, GST-hdor C-tail, GST-FL, GST-DI, and GST-DII. The C-terminal domain of the hKOR-(334 -380), hmor-(336 -394) or hdor-(322-372), NHERF-1/EBP50 (full-length, FL), NHERF-1/EBP50-(1-151) (PDZ domain I, DI), or NHERF-1/EBP50-(152-358) (PDZ domain II, DII) was cloned into the pGEX-4T-1 bacterial expression system, which contains the GST sequence 5Ј to the inserted sequence, and transformed into E. coli BL21-CodonPlus (DE3)-RP to express. The E. coli cells overexpressing GST fusion proteins or GST were solubilized in BugBuster protein extraction reagent at room temperature for 30 min according to the Novagen manual, and then adsorbed onto glutathioneSepharose 4B beads (15 min at room temperature) and washed three times with phosphate-buffered saline. The beads were ready for pulldown analysis, and the amounts of loaded proteins were semiquantified by use of Coomassie Blue staining (SDS-gels) and Ponceau S staining (PVDF membranes), respectively. In addition, those proteins used for overlay assays were further eluted from the beads with 10 mM glutathione/50 mM Tris-HCl (pH 8.0) buffer, and glutathione was removed through multiple rounds of concentration and dilution using Microcon TM centrifugal filter devices with fresh buffer of 25 mM Tris/0.8% NaCl/0.1% Tween 20 (pH 7.6) (TBS-T buffer). The concentrations of the purified proteins were determined by using a BCA protein assay kit.
EXPERIMENTAL PROCEDURES

Materials-OK
cDNA Construction and Purification of His 6 /S Tag-NHERF-1/ EBP50 -NHERF-1/EBP50 cDNA was cloned into the pET-30a(ϩ) bacterial expression vector, which carries N-terminal His 6 tag and S tag, and transformed into E. coli BL21(DE3). The protein was purified from medium by use of ProBond TM nickel-chelating resin according to the manufacturer's instructions. The His 6 tag fusion proteins were eluted from the beads with 0.5 M imidazole/500 mM NaCl/50 mM sodium phosphate buffer, pH 8.0, at room temperature for 20 min. Imidazole was removed in a similar way so as to remove glutathione as above, and the protein concentration was detected by using a BCA protein assay kit.
Cell Culture-CHO cells were cultured in Dulbecco's modified Eagle's medium/Ham's F-12 supplemented with 10% fetal calf serum, 100 units/ml penicillin, and 100 g/ml streptomycin in a humidified atmosphere consisting of 5% CO 2 and 95% air at 37°C. Opossum kidney proximal tubule epithelium cells (OK, OKH, and OKH-N1 cells) were maintained at 37°C in a humidified atmosphere with 5% CO 2 in minimum essential medium supplemented with 10% (v/v) fetal calf serum, penicillin (100 units/ml), and streptomycin (100 g/ml). OKH-N1 cells, transfected stably with full-length rabbit NHERF-1/EBP50 in the pcDNA3.1(ϩ)-Hygro vector, were maintained in the presence of 0.25 mg/ml hygromycin B.
Assessment of Direct Protein-Protein Interactions by Pull-down Techniques-This assessment was performed as described by Einarson and Orlinick (21) .
Interaction of hKOR-C-tail with Purified NHERF-1/EBP50 -GST (control), GST-hKOR C-tail, GST-hmor C-tail, or GST-hdor C-tail bound to glutathione-Sepharose 4B beads at ϳ10 g of each protein/20 l of resin, with less loading of GST-hKOR C-tail due to its poor binding capability. The beads (20 l each) were incubated with purified His 6 /Stag-NHERF-1/EBP50 (10 g), respectively, in 1 ml of TBS-T buffer containing 3% bovine serum albumin at 4°C with end-over-end rotation for 1 h. The beads were washed twice with ice-cold 3% bovine serum albumin in TBS-T buffer and three times with TBS-T buffer to remove nonspecific binding. The Sepharose 4B beads were incubated with 40 l of 2ϫ SDS-PAGE sample buffer at 100°C for 5 min to dissociate proteins from beads and centrifuged to remove beads. The supernatants (20 l of each) were subjected to 15% SDS-PAGE, and the gel was transferred to Immobilon TM -P PVDF membrane, which was rinsed three times with TBS-T buffer and blocked with 2% nonfat dry milk in TBS-T buffer. The His 6 /S tag-NHERF-1/EBP50 fusion protein was detected by blotting with an S-protein HRP conjugate (1:5000), followed by enhanced chemiluminescence reagents. The membranes was also stained with 0.1% Ponceau S in 5% acetic acid to reveal the relative loading amounts of the GST (26 kDa), GST-hKOR C-tail (34 kDa), GST-hmor C-tail (37 kDa), and GST-hdor C-tail (35 kDa).
Interaction of hKOR-C-tail with HA-NHERF-1/EBP50 or Its Fragment Expressed in CHO Cells
-CHO cells were transiently transfected with 8 g/100-mm dish of HA-NHERF-1/EBP50 in pcDNA3, HA-NHERF-1/EBP50-(1-151) (PDZ domain I (DI)) in pBK/CMV, or HA-NHERF-1/EBP50-(152-358) (PDZ domain II (DII)) in pBK/CMV by use of LipofectAMINE (50 l) following the manufacturer's instructions. 2-3 days after transfection, cells were solubilized in lysis buffer (50 mM Tris HCl/150 mM NaCl/1 mM EDTA/1% (v/v) Triton X-100), and centrifuged at 16,000 ϫ g for 30 min. Supernatants were incubated with glutathione-Sepharose 4B beads pre-loaded with either GST or GSThKOR-C-tail as described as above in the 1% Triton X-100/1 mM EDTA/ TBS buffer (25 mM Tris/150 mM NaCl, pH 7.6) at 4°C with end-over-end rotation overnight. The beads were washed three times with ice-cold TBS-T buffer. The proteins were eluted from the beads with 2ϫ SDS-PAGE sample buffer, resolved with 10% SDS-PAGE and transferred onto Immobilon TM -P PVDF membranes. HA fusion proteins were detected with immunoblotting using monoclonal anti-HA antibody (1: 4000) followed by goat anti-mouse IgG-HRP conjugate and enhanced chemiluminescence reagents.
Interaction of hKOR-C-tail with Endogenous NHERF-1/EBP50 in OK Cells-OK cells (ϳ1 ϫ 10 7 ) were lysed and solubilized with 1 ml of lysis buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100) in the presence of Roche Applied Science protease inhibitors mixture (1 tablet/10 ml) for 1 h at 4°C and centrifuged (16,000 ϫ g, 30 min). The supernatants were used for pull-down experiments using beads loaded with either GST-hKOR C-tail or GST as described as above, except that NHERF-1/EBP50 was detected by immunoblotting with a polyclonal anti-rabbit NHERF-1/EBP50 antibody (1:500) followed by goat anti-rabbit IgG-HRP conjugate and enhanced chemiluminescence reagents. (22) . Purified GST and GST fusion proteins (GST-FL, GST-DI, and GST-DII) (2 g/ lane) were separated on 10% SDS-PAGE gels and transferred onto PVDF membranes. Membranes were incubated with purified His 6 -S.tag-NHERF-1/EBP50 (10 g/ml) alone or in the presence of GST or GST-hKOR C-tail at concentration of 10 g/ml in TBS-T containing 5% nonfat milk overnight at 4°C. Membranes were washed three times with 10 ml of TBS-T buffer (10 min each time) and then incubated for 1 h at room temperature with S-protein horseradish peroxidase conjugate at dilution of 1:4000 in the TBS-T buffer for detection of overlaid His 6 -S.tag-NHERF-1/EBP50 proteins. Finally, membrane were washed as above and visualized via enhanced chemiluminescence using an ECL kit.
Detection of NHERF-1/EBP50 Oligomerization by Overlay AssaysThis was performed according the method of Lau and Hall
p42/p44 MAP Kinase Phosphorylation-OK and OKH cells were transferred to 12-well plates, grown overnight, and changed to serum-free medium for 3 h approximately overnight to reduce basal MAP kinase phosphorylation. Cells were treated with or without U50,488H (1 M), naloxone (10 M), or nor-BNI (1 M) at 37°C for 5 min and then lysed with 2ϫ SDS-PAGE sample buffer. For PTXtreated cells, cells were pre-treated with PTX (100 ng/ml, 12-16 h) before incubation with any drugs. Aliquots of the lysates were separated on SDS-PAGE and transferred to Immobilon TM -P PVDF membranes. Phosphorylated MAP kinase was detected by Western blot using a PhosphoPlus p44/42 MAP kinase (Thr 202 /Tyr 204 ) antibody kit according to the manufacturer's instructions. Membranes were then stripped by incubating at 50°C for 30 min with 0.1 mM 2-mecaptoethanol and 2% SDS in 62.5 mM Tris buffer (pH 6.8) and rinsed twice with TBS-T buffer at room temp. Total p44/42 MAP kinase on the membranes was detected by Western blot using p44/42 MAP kinase antibody. Images were captured with a FUJIFILM LAS-1000 imaging system and analyzed with ImageGauge software.
Determination of Intracellular pH (pH i ) in OK, OKH, or OKH-N1 cells-pH i of cells was determined by microphotometry of the fluorescence emission of the pH-sensitive dye, acetoxymethyl ester of 2Ј,7Јbis-(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF-AM), using dual wavelength excitation according to the method of Weinman et al. (23) . Cells were cultured in serum-free medium for overnight on 40-mm glass coverslips to full confluence and loaded with 6.5 M BCECF-AM in 20 mM HEPES buffer, pH 7.4, containing 35 mM NH 4 Cl, 90 mM NaCl, 5 mM KCl, 1 mM MgSO 4 , 2 mM CaCl 2 , 1 mM tetramethylammonium (TMA)-PO 4 , and 25 mM glucose for 20 min at room temperature. Coverslips were transferred to an FSC2 chamber (Bioptechs) and rapidly perfused at a constant flow rate with solutions warmed to 37°C. Cells were acidified for 5 min with 20 mM HEPES, pH 7.5, 130 mM TMA-Cl, 5 mM KCl, 1 mM MgSO 4 , 2 mM CaCl 2 , 1 mM TMA-PO 4 , and 25 mM glucose. Na ϩ /H ϩ exchange transport was initiated by substituting 130 mM NaCl for 130 mM TMA-Cl in the perfusion solution. BCECF fluorescence was measured at excitation wavelengths of 500 and 440 nm and an emission wavelength of 550 nm. The NH 4 Cl pulse was used to achieve an initial pH i of about 6.0, and only cells with initial pH i values between 5.8 and 6.0 were included for analyses. Na ϩ /H ϩ exchange, expressed as change in pH i (⌬pH i )/10 s, represented the initial slope of transport activity measured between 5 and 20 s of sodium-dependent pH i recovery. Over this brief time period, the relationship between pH i and time was essentially linear. To examine the effects of U50,488H and other opioid drugs on Na ϩ /H ϩ exchanger activity, cells were pretreated with the drug(s) during the final 15 min of dye loading and continuously throughout the perfusion process. For PTX-treated cells, cells were pretreated with PTX (100 ng/ml, 12-16 h) before U50,488H treatment. At the end of each experiment, the cells were equilibrated in pH clamp media containing 20 mM HEPES, 20 mM MOPS, 115 mM KCl, 14 mM NaCl, 1 mM MgSO 4 , 1 mM CaCl 2 , 1 mM TMA-PO 4 , 25 mM glucose, and 10 M nigericin at pH 6.2 and 7.3 for calibration of fluorescence intensity with pH. On any given coverslip, Na ϩ /H ϩ exchange was measured in several fields, and the determinations were averaged to constitute a single observation. All measurements were made on cells at the same passage on the same day.
RESULTS
Direct Interaction between the C-terminal Domain of the Human Opioid Receptor (hKOR) and NHERF-1/EBP50 -We
have previously shown that NHERF-1/EBP50 is associated with the hKOR in CHO cells and overexpression of NHERF-1/ EBP50 blocks agonist-induced down-regulation of the hKOR (18). Here we determined whether there was a direct interaction between NHERF-1/EBP50 and C-terminal domain of hKOR by GST fusion protein pull-down techniques. As shown in Fig. 1 , GST-hKOR C-tail bound His 6 -S.tag-NHERF-1/ EBP50, but GST did not, indicating that NHERF-1/EBP50 binds directly to the C-terminal domain of the hKOR. In contrast, the C-tails of human and ␦ opioid receptors did not bind NHERF-1/EBP50, demonstrating the selectivity of the interaction of the hKOR C-tail with NHERF-1/EBP50.
We next determined whether the C-terminal domain of hKOR was associated with NHERF-1/EBP50 expressed in CHO cells. HA-tagged full-length NHERF-1/EBP50 and its two fragments containing PDZ domains I and II were expressed in CHO cells and Triton X-100-solubilized fractions were used for pull-down experiments. Fig. 2A showed that GST-hKOR C-tail strongly bound NHERF-1/EBP50 and its PDZ domain I-containing fragment but not its domain IIcontaining fragment, in cell lysates, whereas GST did not bind significantly to any of the constructs. These results   FIG. 1 . Direct interaction between the hKOR C-tail and NHERF-1/EBP50. Purified His 6 -S.tag-NHERF-1/EBP50 was incubated with glutathione-Sepharose 4B beads pre-loaded with GST, GSThKOR C-tail, GST-hmor C-tail, or GST-hdor C-tail for 1 h at 4°C. The beads were washed extensively, and the bound proteins were eluted from the beads, resolved by 10% SDS-PAGE, and transferred onto an Immobilon TM -P PVDF membrane. A, the His 6 -S.tag-NHERF-1/EBP50 fusion protein was detected by blotting with S-protein HRP conjugate followed by enhanced chemiluminescence reagents. B, the same membrane was stained with 0.1% Ponceau S in 5% acetic, which shows the molecular weights and amounts of the GST and GST fusion proteins loaded. Each figure represents one of the two (GST-hmor C-tail and GST-hdor C-tail) or six (GST-hKOR C-tail and GST) experiments with similar results.
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indicate that NHERF-1/EBP50 expressed in CHO cells interacts with the C-terminal domain of the hKOR and the PDZ domain I is responsible for the interaction. Opossum kidney proximal tubule cells (OK cells) have been shown to express NHERF-1/EBP50 (28) and opioid binding sites endogenously (20) . To test whether the hKOR C-tail interacted with NHERF-1/EBP50 in OK cells, GST pull-down experiments were performed using 1% Triton X-100-soluble fraction of OK cells. As shown in Fig. 2B , GST-hKOR C-tail, but not GST, was associated with a protein band of ϳ50 kDa, which was recognized by a polyclonal anti-rabbit NHERF-1/EBP50 antibody. These results indicate that the C-terminal domain of the opioid receptor binds endogenous NHERF-1/EBP50 in OK cells.
hKOR C-tail Enhanced Oligomerization of NHERF-1/ EBP50 -It has been reported that the NHERF-1/EBP50 oligomerizes via PDZ domains (22, 24 -26) , and binding of the C termini of the ␤ 2 -adrenergic receptor or the platelet-derived growth factor receptor facilitated its oligomerization (22, 25) . Here we examined whether the binding of hKOR C-tail had any effect on NHERF-1/EBP50 oligomerization. GST fusion proteins were subjected to SDS-PAGE and transferred onto membranes, and overlay was performed with His 6 -S.tag-NHERF-1/ EBP50. As shown in Fig. 3 , His 6 -S.tag-NHERF-1/EBP50 bound strongly to GST-NHERF-1/EBP50 and GST-NHERF-1/EBP50 PDZ domain I (Fig. 3A) , but it bound weakly to GST-NHERF-1/EBP50 PDZ domain II and did not bind GST. The results suggest that NHERF-1/EBP50 oligomerization is primarily via its PDZ domain I, consistent with the report of Shenolikar et al. (24, 27) . Binding of His 6 -S.tag-NHERF-1/EBP50 to GST-NHERF-1/EBP50 and GST-NHERF-1/EBP50 PDZ domain I was significantly enhanced by the presence of GST-hKOR Ctail (Fig. 3C) , compared with that in the presence of GST (Fig.  3B) or without GST or any GST fusion protein (Fig. 3A) . The results indicate that the interaction of NHERF-1/EBP50 and hKOR-tail facilitates the PDZ domain I-mediated NHERF-1/ EBP50 oligomerization.
Presence of Opioid Receptors in OK Cells: U50,488H Enhanced p44/42 MAP Kinase Phosphorylation in a Naloxoneand PTX-sensitive
Manner-To determine whether OK cells express functional opioid receptors, we examined whether administration of U50,488H, a selective opioid agonist affected p44/42 MAP kinase phosphorylation. U50,488H enhanced p44/42 MAP kinase phosphorylation by 1.9-to 2.3-fold, compared with the control (Fig. 4) . The U50,488H effect was blocked by either nor-BNI, a selective opioid antagonist, or naloxone, a nonselective opioid antagonist, indicating that the effect of U50,488H is mediated by opioid receptors. In OK cells pretreated with PTX, U50,488H failed to affect p44/42 MAP kinase phosphorylation (Fig. 4) , demonstrating that opioid receptor stimulation of p44/42 MAP kinase phosphorylation is dependent on activation of the G i /G o proteins in OK cells.
U50,488H Stimulated NHE3 Activity in OK Cells via Opioid Receptor in a PTX-insensitive Manner-Whether activation of opioid receptors regulated Na
ϩ /H ϩ exchange was investigated in OK cells, which express only NHE3 among the subtypes of Na ϩ /H ϩ exchangers (28) . Following intracellular acidification, control OK cells had an initial ⌬pH i /10 s (a measure of Na ϩ /H ϩ exchange rate) of 0.030 Ϯ 0.002 (n ϭ 9) (Fig. 5, A and  C) . In the presence of U50,488H, the ⌬pH i /10 s was increased to 0.043 Ϯ 0.003 (n ϭ 7) (Fig. 5, A and C) , which was significantly different from the control (p Ͻ 0.01). Naloxone, which by itself had no effect (⌬pH i /10 s ϭ 0.032 Ϯ 0.002, n ϭ 4), blocked U50,488H-induced enhancement (⌬pH i /10 s ϭ 0.028 Ϯ 0.001, n ϭ 4) (Fig. 5, A and C) 
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pretreated with PTX, the ⌬pH i /10 s of control cells and U50,488H-treated cells were 0.031 Ϯ 0.002 (n ϭ 4) and 0.044 Ϯ 0.002 (n ϭ 4) (Fig. 5 , B and C), respectively, which were similar to corresponding data in cells not treated with PTX. The PTX treatment paradigm was shown previously to completely abolish agonist-induced increase in [ 35 S]GTP␥S binding mediated by opioid receptors (29) . These results indicate that stimulation of NHE3 activity by opioid receptor activation is not mediated by G i /G o proteins.
U50,488H Failed to Stimulate NHE3 Activity in OKH Cells, Which Express a Much Lower Level of NHERF-1/EBP50 -
Because the stimulatory effect of opioid receptor on NHE3 activity in OK cells is independent of G i /G o proteins, we investigated whether the effect was mediated by the association of the opioid receptor with NHERF-1/EBP50. The OKH cell line is a subclone of OK cells, which were shown to express a much lower level of NHERF-1/EBP50 compared with OK cells (30) . The lower expression of NHERF-1/EBP50 in OKH cells was confirmed by immunoblotting (Fig. 6A, the top panel) , whereas the expression levels of G␣ i (the middle panel) were similar. Incubation of OKH cells with U50,488H did not have any effect on NHE3 activity (Fig. 7A) . Control and U50,488H-treated OKH cells had initial rates of Na ϩ /H ϩ exchange (⌬pH i /10 s) of 0.025 Ϯ 0.003 (n ϭ 4) and 0.023 Ϯ 0.002 (n ϭ 4). In OKH cells U50,488H enhanced p44/42 MAP kinase phosphorylation by ϳ2-fold, similar to that in OK cells, which was blocked by naloxone and PTX pretreatment (Fig. 6B) , indicating that opioid receptor-G i /G o proteins signaling pathway is still intact. These results suggest that acceleration of Na ϩ /H ϩ exchange following opioid receptor activation is independent of G i /G o proteins and mediated by NHERF-1/EBP50 in OK cells.
Transfection of NHERF-1/EBP50 into OKH Cells Restored the Ability of U50,488H
to Stimulate NHE3 Activity-We used OKH-N1 cells to further explore the role of NHERF-1/EBP50 in U50,488H-induced increase in Na ϩ /H ϩ exchange. OKH-N1 cells are OKH cells stably transfected with the full-length rabbit NHERF-1/EBP50 at an expression level comparable to that in OK cells (Fig. 6A, top panel) . These cells expressed a similar level of G␣ i , compared with either OK or OKH cells (Fig. 6A, the middle panel) . Following acidification of OKH-N1 cells, U50,488H significantly increased the ⌬pH i /10 s, compared with the untreated control (p Ͻ 0.05, n ϭ 6) (Fig. 7B) . These results further support the notion that U50,488H stimulated Na ϩ /H ϩ exchange is mediated by NHERF-1/EBP50.
DISCUSSION
NHERF-1/EBP50 Binds to the C-tail of the Opioid Receptor via the First PDZ Domain-
We have previously shown that the hKOR co-immunoprecipitated with NHERF-1/EBP50, and a PDZ domain-mediated interaction has been proposed to occur between the C-tail of the hKOR and NHERF-1/EBP50 (18) . In this study, using pull-down techniques, we show that the hKOR C-tail interacted directly with NHERF-1/EBP50, purified from bacterial expression system or expressed in CHO cells, via its PDZ domain I and bound endogenous NHERF-1/ EBP50 in OK cells. Notably the interaction of the hKOR C-tail with NHERF-1/EBP50 expressed in CHO cells was much stronger than its association with NHERF-1/EBP50 purified from bacterial expression system, which is probably due to lack of post-translational modifications of proteins in bacteria. The binding of NHERF-1/EBP50 to the C-tail of the hKOR is much weaker than its binding to the C-tail of the ␤ 2 -adrenergic receptor. 2 This finding is consistent with the observation that the C-terminal sequence of the hKOR, NKPV, is distinctly 
FIG. 5. U50,488H stimulated Na
؉ /H ؉ exchange in OK cells independent of PTX-sensitive G proteins. A, effects of U50,488H and/or naloxone on Na ϩ -dependent pH i change. B, effects of PTX pretreatment on the U50,488H action. OK cells grown on coverslips were loaded with BCECF-AM, acidified, and intracellular pH (pH i ) was determined after switching to Na ؉ -containing buffer (at time 0) as described under "Experimental Procedures." A, cells were treated with 1 M U50,488H, 10 M naloxone, or both during the final 15 min of dye loading and continuously throughout the perfusion process. B, cells were pre-treated with PTX (100 ng/ml, 12-16 h) before incubation with 1 M U50,488H as in A. A and B show representative data of Na ؉ -dependent pH i changes in the first 30 s. C, initial rates of pH i changes (⌬pH i /10 s) are calculated based on pH i changes between 5 and 20 s of sodium-dependent pH i recovery as described under "Experimental Procedures." On any given coverslip, Na ϩ /H ϩ exchange was measured in several fields, and the determinations were averaged to constitute a single observation. Each value represents the mean Ϯ S.E. of at least four independent experiments with duplicate coverslips. #, p Ͻ 0.01, compared with cells without opioid drug treatment by one-way analysis of variance followed by Dunnett's multiple comparison test.
Opioid Receptor Enhances Na ϩ /H ϩ Exchange via NHERF-1/EBP50
different from the sequence, D(S/T)XL, the optimal C-terminal motif in the ␤ 2 -AR for EBP50/NHERF binding (19) . Although the opossum opioid receptor has not been cloned, it is very likely that the four amino acids of the C-terminal domain are identical to those in the hKOR as they are conserved in the human, guinea pig, rat, and mouse KORs (31) (32) (33) (34) . Activation of Opioid Receptors Enhanced NHE3 Activity via NHERF-1/EBP50 -In OK cells, the selective agonist U50,488H enhanced Na ϩ /H ϩ exchange in a naloxone-sensitive manner. Because the NHE3 is the only subtype of NHEs in OK cells (28) , these results indicate that U50,488H stimulated NHE3 activity via opioid receptors. Interestingly, the stimulatory effect is PTX-resistant, indicating that opioid receptor regulates the activity of NHE3 by a mechanism independent of activation of G i /G o proteins, which are the predominant G proteins coupled to the receptor (5) . In OKH cells that express a much lower NHERF-1/EBP50 level, opioid receptor activation did not affect NHE3 activity; although it enhanced p42/p44 MAP kinase phosphorylation similar to that in OK cells. Moreover, stably transfecting NHERF-1/EBP50 into OKH cells restored the stimulatory effect of opioid receptors on NHE3 activity as shown in OKH-N1 cells. Thus, opioid receptor regulation of NHE3 activity is NHERF-1/EBP50-dependent.
It should be noted that OK, OKH, and OKH-N1 cells express similar levels of total G␣ i proteins, thus excluding their role in regulation of Na ϩ /H ϩ exchange. The opioid receptors have been shown to couple to G o proteins in addition to G i proteins. However, by use of rabbit polyclonal anti-rat G␣ o antibody (Calbiochem), we were not able to detect specific bands in the three cell lines. One possibility is that OK cells have low or no G␣ o , because G o proteins have been reported to be predominantly expressed in neuronal cells. Another likely scenario is that the anti-rat G␣ o antibody may not recognize opossum G␣ o proteins. The opioid receptor, like many other G i /G o -coupled receptors, has been demonstrated also to interact with PTXinsensitive G proteins, such as G z (35) , G 16 (36) , and G s (37) . However, these G proteins are not likely to be involved in the observed stimulation of NHE3 by opioid receptor activation, because G z is predominantly expressed in neuronal tissues (38, 39) and G 16 is expressed only in hemopoietic cells (40) . In addition, stimulation of G s proteins has been shown to inhibit NHE3 activity (41) . G q proteins have not been reported to be coupled to opioid receptors (5). Thus, this NHERF-1/EBP50-dependent mechanism is unlikely to be mediated by these heterotrimeric G proteins. Lin et al. (42) reported that G 12 and G 13 proteins stimulated NHE3 activity. By immunoblotting, we found that the three cell lines expressed G␣ 12 and G␣ 13 , and OKH and OKH-N1 cells have higher expression levels of both G proteins than OK cells (data not shown). To the best of our knowledge, opioid receptors have not been shown to couple to G 12 and G 13 proteins. However, the possibility cannot be ruled out that G 12 and G 13 may play a role in opioid receptormediated stimulation of NHE3 activity.
The current study provides the first direct evidence that, through association with NHERF-1/EBP-50, a GPCR enhances NHE3 activity, although stimulation of NHE3 by the ␤ 2 -AR acting via NHERF-1/EBP-50 is implicit in the findings of Hall et al. (17) . Interaction of NHERF-1/EBP-50 with NHE3 has been demonstrated to be critical for cAMP-mediated inhibition of NHE3 activity (27) . However, activation of the ␤ 2 -AR does not result in inhibition of NHE3 activity, unlike that of other G s -coupled receptors such as the parathyroid hormone receptor (41) . NHERF-1/EBP-50 binds to the C terminus of the ␤ 2 -AR via PDZ domain-mediated interaction (17) . When the interaction is disrupted by mutation in the ␤ 2 -AR, activation of the mutant receptor, which enhanced cAMP formation similar to the wild-type, leads to inhibition of the NHE3 activity. These results suggest that the lack of inhibition following activation of the ␤ 2 -AR is likely to be due to two opposing effects on NHE3: cAMP-mediated inhibition via G s proteins and stimulation via interaction with NHERF-1/EBP50 independent of G s . Activation of opioid receptors in rat cardiac myocytes increased pH i by enhancing Na ϩ /H ϩ exchange, which is dependent on PKC activation (43, 44) . This PKC-related mechanism is likely to be mediated by PTX-sensitive G proteins through the ␤␥ subunits, because receptor activation in the heart causing another effect, arrhythmia, involves PTX-sensitive G proteins, phospholipase C, and PKC pathway (45) . However, NHERF-1/ EBP50 may not be involved, because NHE1 is the main Na ϩ /H ϩ exchanger present in cardiomyocytes (46, 47) . Mechanisms Underlying Stimulation of NHE3 Activity following Activation of Opioid Receptors-How opioid receptor interacts with NHERF-1/EBP50 to stimulate NHE3 in OK cells remains to be investigated. NHERF-1/EBP50 is associated with NHE3 and ezrin, which was proposed to bind to cAMPdependent protein kinase (PKA) (27) . NHERF-1/EBP50 thus brings the ezrin-PKA complex into proximity of the tail of NHE3. This juxtaposition is believed to facilitate NHE3 phosphorylation by PKA, resulting in reduction of NHE3 activity (27) .
Hall et al. (17) and Weinman et al. (24, 27) have proposed that when ␤ 2 -AR is activated by an agonist, the receptor binds NHERF-1/EBP50 with such a high affinity that it displaces NHE3 binding, resulting in disinhibition of NHE3 function. Although it remains possible that the opioid receptor competes with NHE3 for NHERF-1/EBP50 as the ␤ 2 -AR, the affinity of the opioid receptor for NHERF-1/EBP50 is considerably less. Accordingly, we favor an alterative hypothesis whereby the opioid receptor promotes the oligomerization of NHERF-1. If a basal level of PKA activity is present in OK cells to maintain NHERF-1/EBP50-mediated inhibition of NHE3, activation of the opioid receptor enhances its association with NHERF-1/EBP50 binding and causes oligomerization of NHERF-1/EBP50, which, in turn, eliminates the inhibition of NHE3 by NHERF-1/EBP50 to unmask the stimulatory effect. Our previous observation, that pretreatment of CHO cells expressing the hKOR and NHERF-1/EBP50 with U50,488H increased the amount of NHERF-1/EBP50 co-immunoprecipitated with the hKOR (18) , supports this hypothesis. NHERF-1/EBP50 oligomers may represent a pool of inactive NHERF-1/EBP50, which is incapable of inhibiting NHE3 (24, 27) . Here we showed that the hKOR C-tail promoted oligomerization of NHERF-1/EBP50, similar to the C-terminal domain of the platelet-derived growth factor receptor or the ␤ 2 -AR (22, 25) . The oligomerization of NHERF-1/EBP50 may render it inactive in inhibiting NHE3. The opioid receptor stimulatory effect on NHE3 in OK cells is thus revealed.
We recognize that the association between the opioid receptor, NHERF-1/EBP-50, and NHE3 may also involve other signaling pathways. NHERF-1/EBP50 has been shown to associate with a variety of signaling protein(s) that might affect NHE3 function directly or indirectly, including phospholipase C ␤1 and ␤2 isoforms (48, 49) , a receptor for activated C kinase (50), EPI64 (51), nadrin (51) , and ERM proteins (52) . ERM proteins, as conformationally regulated binding sites for NHERF-1/EBP50, have been implicated in regulating the Rho and Rac signaling pathways (52, 53) . One or several of these NHERF-1/EBP50-associated proteins may affect NHE3 function by yet unidentified mechanisms, which may be regulated by the opioid receptor activation in an NHERF-1/EBP50-dependent mechanism.
Use of OK Cells in the Study-Whether activation of opioid receptors regulated Na ϩ /H ϩ exchange was investigated in OK cells, because these cells have been shown to express NHERF-1/EBP50, NHE3, and opioid binding sites endogenously (20, 28 
CONCLUSION
In conclusion, we have shown that NHERF-1/EBP50 binds directly to the C-tail of the opioid receptor through its first PDZ domain and that this interaction plays an important role in stimulation of NHE3 activity mediated by the opioid receptor independent of PTX-sensitive G proteins. We have observed that opioid receptor mRNA is present in the rat kidney as determined by RT-PCR, 3 and it is therefore plausible that opioid agonists may stimulate NHE3 in renal proximal tubules via a PDZ domain-mediated interaction between the opioid receptor and NHERF-1/EBP50. Although the physiological significance of our finding is presently unknown, the NHERF-1/ EBP50-dependent regulation of Na ϩ /H ϩ exchange by opioids may potentially play a role in the regulation of proximal tubule sodium and hydrogen ion transport.
